A short term post-doctoral position is immediately available in the laboratory of prof. Licio Collavin at the University of Trieste (http://tinyurl.com/collavinlab) The lab is focused on the molecular mechanisms that determine cancer aggressiveness, with a special interest in function and regulation of the tumor suppressor DAB2IP, a Ras-GAP and signaling adaptor that modulates multiple oncogenic pathways. For more information, or to apply, feel free to write directly to prof. Collavin
The goal of our lab at the San Raffaele – Telethon institute for Gene Therapy (SR-TIGET) in Milan is to study the regulation of blood cell emergence during human embryonic development. To this aim, we use our innovative hESCs/hiPSCs platform and combine developmental cell and molecular biology to understand normal and pathological human hematopoietic development, with a particular interest in studying the genetic origins for blood disorders and developing novel strategies for their treatment.
A two-year post-doc position on the project entitled “The lncRNA PHOX2B-AS1 in the pathogenesis and as potential drug target in Congenital Central Hypoventilation Syndrome (CCHS)” founded by the Telethon Foundation, is available at the “Molecular Pharmacology” laboratory (PI Prof. Fornasari), Dept. of Medical Biotechnology and Translational Medicine, University of Milan.
We are looking for a highly motivated and enthusiastic individual to study the process of inflammation. In particular, the selected candidate will investigate the role of intracellular immune receptors in shaping immune responses under physiological and pathological conditions, such as chronic inflammatory diseases. These studies will collectively advance our understanding of inflammatory disorders and improve patients’ care.
Background Gene co-expression networks have been used to define prognostic gene signatures and centrally connected genes as therapeutic targets in cancer. However, most of these studies are purely descriptive, not fully exploiting the wealth of information hidden in the constructed networks to investigate specific biological hypotheses. Moreover, networks have never been compared across breast cancer (BC) subtypes, despite the potential usefulness of such an approach to understand how specific molecular features are established and regulated. Hypothesis We posited that reconstructing BC transcriptional networks could allow us to address biological questions related both to BC in general and to specific BC sub-types. Allowing to formulate testable hypotheses about how biologically/clinically relevant gene expression patterns are established and maintained in specific BC sub-types, such an approach could be exploited to identify and validate potential key regulatory genes, developing them into therapeutic targets. Aims We have implemented a workflow based on the analysis of the METABRIC BC gene expression dataset, which we have validated both based on database analyses and on experimental approaches. We aim at confirming its validity as a tool to dissect molecular pathways linked to BC aggressiveness, particularly basal-like BC for which a targeted treatment is still lacking, identifying key regulatory genes amenable to therapeutic intervention. AIM 1) Discovering how clinically relevant BC gene expression patterns are established by identifying transcriptional regulatory hubs and validating them as therapeutic targets. AIM2 ) Identifying drugs able to target relevant co-expression modules via a drug repositioning approach. AIM 3) Identifying central regulators of specific stromal signatures. AIM 4) demonstrating siRNA-mediated in vivo target ability of identified transcriptional regulators